4-[(4-formylphenoxy)methyl]-2,2-dimethyl-1,3-dioxolane | 91944-48-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-[(4-formylphenoxy)methyl]-2,2-dimethyl-1,3-dioxolane
• 英文别名: 4-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]benzaldehyde
• CAS: 91944-48-8
• 化学式: C₁₃H₁₆O₄
• 分子量: 236.268
• InChiKey: PLNIKRYRJIYPER-UHFFFAOYSA-N

物化性质

• 沸点：
  357.6±22.0 °C(Predicted)
• 密度：
  1.123±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-[(4-formylphenoxy)methyl]-2,2-dimethyl-1,3-dioxolane 在 吡啶 、 盐酸 、 ammonium hydroxide 、 sodium methylate 、 吡啶盐酸盐 作用下， 以 甲醇 、 二氯甲烷 、 丙酮 为溶剂， 反应 13.5h， 生成 3--1,2-epoxypropane
  参考文献：
  名称：

  .beta.1-Selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazole class

  摘要：

  A series of 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazoles is described. The compounds were investigated in vitro for beta-adrenoceptor antagonism, and several examples were found to be selective for the beta 1-adrenoceptor. The structure--activity relationship exhibited by this series of compounds is discussed. (S)-2-[p-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-hydroxypropoxy]phenyl]-4-(2 -thienyl)imidazole [(S)-13] was over 100 times more selective than atenolol for the beta 1-adrenergic receptor and has been selected for in-depth studies.

  DOI：

  10.1021/jm00361a004
• 作为产物：
  描述：

  对羟基苯甲醛 在 三苯基膦 、 偶氮二甲酸二异丙酯 作用下， 以 四氢呋喃 为溶剂， 反应 16.5h， 以21%的产率得到4-[(4-formylphenoxy)methyl]-2,2-dimethyl-1,3-dioxolane
  参考文献：
  名称：

  [DE] SUBSTITUIERTE PHENYLAMINOTHIAZOLE UND IHRE VERWENDUNG
  [EN] SUBSTITUTED PHENYLAMINOTHIAZOLES AND USE THEREOF
  [FR] PHENYLAMINOTHIAZOLES SUBSTITUES, ET LEUR UTILISATION

  摘要：

  这份申请涉及新的苯基氨基噻唑衍生物，其制备方法，它们在治疗和/或预防疾病方面的使用以及它们用于制造用于治疗和/或预防疾病的药物，特别是用于治疗和/或预防高血压和其他心血管疾病。

  公开号：

  WO2006027142A1

文献信息

• AMINO ACID ESTER PRODRUGS AND THE USE THEREOF
  申请人：Meibom Daniel

  公开号：US20110237629A1

  公开（公告）日：2011-09-29

  The present application relates to amino acid ester prodrug derivatives of 2-amino-6-([2-(4-chlorophenyl)-1,3-oxazol-4-yl]methyl}sulfanyl)-4-(4-[2,3-dihydroxypropyl]oxy}phenyl)pyridine-3,5-dicarbonitriles, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of cardiovascular disorders.

  本申请涉及2-氨基-6-([2-(4-氯苯基)-1,3-噁唑-4-基]甲基}硫基)-4-(4-[2,3-二羟基丙基]氧基}苯基)吡啶-3,5-二羧腈的氨基酸酯前药衍生物，其制备方法，它们用于治疗和/或预防疾病的用途，以及它们用于制造用于治疗和/或预防疾病的药物，特别是心血管疾病。
• Substituted Phenylaminothiazoles and Use Thereof
  申请人：Erguden Jens-Kerim

  公开号：US20080269300A1

  公开（公告）日：2008-10-30

  The present application relates to novel phenylaminothiazole derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of hypertension and other cardiovascular disorders.

  本申请涉及新型苯基氨基噻唑衍生物，其制备方法，其用于治疗和/或预防疾病的用途，以及其用于制备治疗和/或预防疾病的药物的用途，优选用于治疗和/或预防高血压和其他心血管疾病。
• Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating Diseases
  申请人：Nell Peter

  公开号：US20100048641A1

  公开（公告）日：2010-02-25

  The present invention relates to the use of A1 and/or dual A1/A2 b agonists of the formulae (IA) and (IB) for preparing a medicament for treating dyslipidemia, metabolic syndrome and diabetes and dyslipidemia, metabolic syndrome and diabetes in association with hypertension and cardiovascular disorders.

  本发明涉及使用式（IA）和（IB）的A1和/或双重A1/A2受体激动剂制备治疗失调脂质、代谢综合征和糖尿病以及与高血压和心血管疾病相关的失调脂质、代谢综合征和糖尿病的药物。
• Ring-Opening Reactions of Epoxides Catalyzed by Molybdenum(VI) ­Dichloride Dioxide
  作者：Dillip Chand、Kandasamy Jeyakumar

  DOI：10.1055/s-2008-1032163

  日期：2008.3

  alcohols, acetonides, and α-alkoxy ketones is achieved by using molybdenum(VI) dichloride dioxide (MoO 2 Cl 2 ) as a catalyst. Alcohol, aldehyde, oxime, tosyl, and TERT-butyldimethylsilyl functional groups are tolerated during the methanolysis and acetonidation of the functionalized epoxides. No polymerization product is observed with any of the epoxides. Direct conversion of epoxides devoid of sensitive

  通过使用二氯化钼 (VI) 二氧化 (MoO 2 Cl 2 ) 作为催化剂，可以将环氧化物转化为 β-烷氧基醇、丙酮化物和 α-烷氧基酮。在官能化环氧化物的甲醇分解和丙酮化过程中，醇、醛、肟、甲苯磺酰基和叔丁基二甲基甲硅烷基官能团是可耐受的。没有观察到任何环氧化物的聚合产物。通过使用 MoO 2 Cl 2 /Oxone 系统，可以在一个步骤中将不含敏感官能团的环氧化物直接转化为相应的 α-甲氧基酮。
• DIPEPTOID PRODRUGS AND THE USE THEREOF
  申请人：Lerchen Hans-Georg

  公开号：US20110294719A1

  公开（公告）日：2011-12-01

  The present application relates to dipeptide-like prodrug derivatives of 2-amino-6-([2-(4-chlorophenyl)-1,3-oxazol-4-yl]methyl}sulfanyl)-4-(4-[2,3-dihydroxypropyl]oxy}phenyl)pyridine-3,5-dicarbonitrile, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of cardiovascular disorders.

  本申请涉及2-氨基-6-([2-(4-氯苯基)-1,3-噁唑-4-基]甲基}硫基)-4-(4-[2,3-二羟基丙基]氧基}苯基)吡啶-3,5-二羧腙的二肽类前药衍生物，其制备方法，它们用于治疗和/或预防疾病，以及它们用于制造用于治疗和/或预防疾病的药物，特别是心血管疾病。